Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Herantis Pharma Oyj (HRTIS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.415 +0.025    +1.80%
11:23:37 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 12,418
  • Bid/Ask: 1.410 / 1.450
  • Day's Range: 1.385 - 1.440
Type:  Equity
Market:  Finland
ISIN:  FI4000087861 
S/N:  20160733
Herantis Pharma Oyj 1.415 +0.025 +1.80%

Herantis Pharma Oyj Company Profile

 
Get an in-depth profile of Herantis Pharma Oyj, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

10

Equity Type

ORD

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). Its lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.

Contact Information

Address Bertel Jungin Aukio 1
Espoo, 02600
Finland
Phone 358 9222 1195
Fax -

Top Executives

Name Age Since Title
Seppo Kaakkola - - Member of Scientific Advisory Board
Alan Whone - - Member of Scientific Advisory Board
Mart Saarma - - Member of Scientific Advisory Board
Kari Alitalo - - Member of Scientific Advisory Board
Timo Ilari Veromaa 61 2012 Independent Chairman of the Board
Aki Pellervo Prihti - 2014 Director
Anders Gersel Pedersen 72 2021 Chairman of Scientific Advisory Board
Frans Gustaf Wuite - 2014 Director
Hilde Furberg 65 2021 Director
Alberto J Espay - 2021 Member of Scientific Advisory Board
Daniele Bravi - 2021 Member of Scientific Advisory Board
Mats Thoren 52 2020 Director
David Dexter - 2021 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HRTIS Comments

Write your thoughts about Herantis Pharma Oyj
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email